Nevanac licensed for diabetic indication

Nevanac (nepafenac) is now indicated to reduce the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

Diabetic patients have a slightly higher risk of developing macular oedema following ocular surgery
Diabetic patients have a slightly higher risk of developing macular oedema following ocular surgery

In a double-blind, randomised, vehicle-controlled study, patients with diabetes were randomised to receive either nepafenac eye drops or placebo 3 times daily. Medication was initiated the day prior to surgery, and continued on the day of surgery and for up to 90 days of the postoperative period. The study showed that a significantly greater proportion of patients developed macular oedema in the vehicle group (16.7%) than in the nepafenac group (3.2%).

View Nevanac drug record

Further information: Alcon Laboratories UK Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases